secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2023-10-18T23:59:59+00:00
Accession:  0001104659-23-109878
Event type: regulatory
Sentiment:  positive
Materiality: 0.72
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute receives EMA PRIME eligibility for RZ358 in congenital hyperinsulinism
-------------------------------------------------------------------------------

- EMA grants PRIME eligibility to RZ358 for congenital HI, citing unmet medical need and positive Phase 2b data.
- PRIME provides enhanced regulatory support to accelerate development and evaluation.
- Phase 3 study for RZ358 planned to initiate in Q4 2023.
- Phase 2b RIZE study showed ~75% average improvement in hypoglycemia at intended Phase 3 doses.
- Improvement was consistent across age groups (2-6, 6-12, >12 years).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923109878/0001104659-23-109878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923109878/tm2328622d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-109878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer